Zerion Pharma and Insud Pharma have announced a collaboration to develop and commercialize drug products using ZERION’s innovative Dispersome® technology. Under this partnership, ZERION will develop Dispersome® formulations of marketed drug products while Insud Pharma will be responsible for the finished product dosage form, the clinical development as well as global marketing and sales of the final products.
The partnership with Insud Pharma has yielded positive results from the first human clinical study of a Dispersome® formulation of the drug Ivacaftor, a pharmaceutical used to treat cystic fibrosis.The study, involving 18 healthy volunteers, showed enhanced bioavailability. One of the Ivacaftor Dispersome® formulations showed improved bioavailability compared to the reference product, while the pharmacokinetic parameters for the second formulation were equivalent to Kalydeco®. Both Ivacaftor Dispersome® formulations carried high content (drug load) of Ivacaftor and were designed to increase the solubility of this poorly soluble compound.
Read more →May 13, 2024 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces positive results from the first human clinical study of a Dispersome® formulation of the drug Ivacaftor, a pharmaceutical used to treat cystic fibrosis. The study was conducted by ZERION’s Spanish partner...
- The two companies have started collaborating on the first two drug products and expect to expand their portfolio. AUGUST 29, 2022 (COPENHAGEN, Denmark). The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their...
“We are striving to launch innovative medicinal products that in addition to being price-competitive provide additional benefits to the patients. We believe that ZERION’s technology can offer such benefits and have been very pleased with the results, we have seen thus far. We are happy to announce this collaboration that highlights the capabilities of ZERION in the field of drug formulation and the great team that makes it possible.”
